Disclaimer: This article is for informational and educational purposes only. It does not constitute medical or legal advice. The regulatory landscape described here is subject to change. Consult a licensed healthcare provider for health-related decisions and a qualified attorney for legal guidance regarding compounding regulations. Information is current as of April 2026.
If you've followed peptide research over the past three years, you've almost certainly encountered the phrases "Category 1," "Category 2," and "Category 3." They appear in news headlines, regulatory discussions, and across research forums — often with very little explanation of what they actually mean.
These categories are not arbitrary labels. They are part of a specific FDA interim policy framework that determines which bulk drug substances may be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) — and which may not.
Understanding these categories matters. They determine the legal landscape for compounding pharmacies, shape the availability of research-grade compounds, and sit at the center of the most significant peptide regulatory shift in U.S. history.
This guide explains each category from the ground up: where they come from, what they mean, how substances move between them, and where things stand after the 2026 reclassification announcement.
The Regulatory Foundation: Section 503A and the Bulks List
Before the categories make sense, you need to understand the system they operate within.
Section 503A of the FD&C Act establishes the legal framework for traditional pharmacy compounding in the United States. Under this section, state-licensed pharmacies and physicians may compound drug products using bulk drug substances — but only if those substances meet one of three criteria [1]:
- They comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, along with the USP chapter on pharmacy compounding.
- They are components of FDA-approved drug products, if no applicable USP or NF monograph exists.
- They appear on the FDA's 503A bulks list — a specific, formally maintained list of bulk drug substances authorized for compounding — if neither of the first two conditions is met.
Additionally, all bulk drug substances used in compounding must be accompanied by a valid certificate of analysis (COA) and manufactured by an establishment registered with the FDA under Section 510 of the FD&C Act [1].
The 503A bulks list itself is relatively small. The FDA placed six substances on the list via a final regulation in February 2019 and proposed adding five more (while declining 26 others) in September 2019 [1]. The formal rulemaking process is deliberate and slow.
That's where the interim policy comes in.
Why the FDA Created the Three-Category System
The formal 503A bulks list covers only a handful of substances. But hundreds of bulk drug substances have been nominated for potential inclusion — many of them peptides.
To avoid disrupting access to compounds while it evaluated those nominations, the FDA developed an interim policy describing the conditions under which it would — or would not — exercise enforcement discretion [1][2].
In plain language: the FDA acknowledged it couldn't evaluate every nominated substance immediately, so it created a temporary classification system to signal which substances it considered acceptable for compounding in the meantime and which it did not.
That system has three tiers.
Category 1: Eligible for Enforcement Discretion
What it means:
Category 1 substances are those that have been nominated for inclusion on the 503A bulks list with sufficient supporting information for the FDA to evaluate them. They do not appear on any other restrictive list, and the FDA has not identified disqualifying safety concerns [1][2].
The critical detail: the FDA does not intend to take enforcement action against compounders using Category 1 substances, provided the conditions described in the agency's interim guidance are met [1].
What it does not mean:
Category 1 is not FDA approval. It is not a formal determination that a substance belongs on the 503A bulks list. It is an exercise of enforcement discretion — a regulatory decision not to act against compounders while evaluation continues.
The distinction matters. An FDA-approved drug has undergone rigorous clinical review. A Category 1 substance has been nominated with adequate supporting documentation and has not raised safety flags during preliminary review. These are fundamentally different regulatory statuses.
Practical implications:
- Compounding pharmacies may compound using Category 1 bulk drug substances under the conditions outlined in the FDA's interim guidance.
- The substance remains under evaluation. The FDA may ultimately add it to the 503A bulks list, decline to add it, or move it to a different category based on new information.
- If the FDA later identifies safety concerns, it may remove a substance from Category 1 [1].
Category 2: Identified Safety Risks — No Enforcement Discretion
What it means:
Category 2 substances are those that were nominated with sufficient supporting information — just like Category 1 — and may be eligible for inclusion on the 503A bulks list. However, the FDA has identified significant safety risks relating to their use in compounding and has determined that it does not intend to extend the same enforcement discretion it applies to Category 1 [1][2].
When the FDA places a substance in Category 2, it publishes the safety information describing the identified risks on FDA.gov and notifies the public that the substance has been added [1].
What it does not mean:
Category 2 is not a permanent ban. It is not a final determination that the substance cannot be compounded. It indicates that the FDA has found enough evidence of potential risk to withhold enforcement discretion while it continues evaluation.
Practical implications:
- The FDA would consider taking enforcement action against a compounder using a Category 2 substance under its general enforcement policies [1].
- Compounding pharmacies face significant legal and regulatory risk if they compound using Category 2 substances.
- A substance can move out of Category 2 if the FDA's evaluation resolves the identified safety concerns — or if the agency's position changes through formal rulemaking or policy revision.
Why this category became the center of controversy:
Between late 2023 and December 2024, the FDA moved 19 previously Category 1 peptide substances to Category 2 — the largest such reclassification in the history of the 503A interim policy [3][4][5]. The FDA cited various safety concerns including immunogenicity risks, manufacturing impurity concerns, and limited clinical data [4].
Industry groups and compounding pharmacy advocates challenged many of these reclassifications, arguing that the FDA had not identified specific safety signals for each individual substance sufficient to justify the restriction [4][5].
Category 3: Insufficient Information — Under Review
What it means:
Category 3 substances are those that may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for the FDA to evaluate them [1][2].
What it does not mean:
Category 3 does not indicate that the FDA has found safety problems. It means the agency doesn't have enough data to make a determination either way.
Practical implications:
- Category 3 substances are not eligible for the enforcement discretion that applies to Category 1 [1].
- The FDA would consider taking enforcement action against a compounder using a Category 3 substance.
- The substances can be re-nominated with sufficient supporting information through the FDA's public docket process [1].
- If re-nominated with adequate documentation, the FDA would evaluate them and potentially place them in Category 1 or Category 2.
Side-by-Side Comparison: Category 1 vs. Category 2 vs. Category 3
Nomination status
- Category 1: Sufficient information provided
- Category 2: Sufficient information provided
- Category 3: Insufficient information provided
FDA safety finding
- Category 1: No identified safety concerns
- Category 2: Significant safety risks identified
- Category 3: Not evaluated (insufficient data)
Enforcement discretion
- Category 1: Yes — FDA does not intend to act
- Category 2: No — FDA may take action
- Category 3: No — FDA may take action
Compounding eligibility
- Category 1: Permitted under interim policy conditions
- Category 2: Not permitted under interim policy
- Category 3: Not permitted under interim policy
Path forward
- Category 1: Continued evaluation for 503A bulks list
- Category 2: Further evaluation; possible reclassification
- Category 3: Re-nomination with sufficient data
How Substances Move Between Categories
The category system is not static. Substances can and do move between categories based on new information, FDA evaluation outcomes, and policy decisions.
Category 1 → Category 2
This occurs when the FDA identifies safety concerns about a substance that was previously considered acceptable under enforcement discretion. The most prominent example: the 2023–2024 reclassification of 19 peptide substances from Category 1 to Category 2 [3][4][5].
Category 2 → Category 1
This occurs when previously identified safety concerns are resolved or reassessed. In September 2024, the FDA removed five peptide substances from Category 2 and referred them to the Pharmacy Compounding Advisory Committee (PCAC) for evaluation — an intermediate step that signaled potential movement back toward Category 1 [6][7].
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides would be moved from Category 2 back to Category 1 [4][5]. As of April 2026, the formal reclassification has not yet been published in the Federal Register, and the specific list of affected substances has not been officially confirmed [4][5].
Category 3 → Category 1 or Category 2
This occurs when a substance is re-nominated with sufficient supporting information. The FDA evaluates the new submission and places the substance in whichever category its review supports.
Any Category → 503A Bulks List (or Declined)
The ultimate destination for any nominated substance is a formal FDA determination: either inclusion on the 503A bulks list (making compounding formally authorized) or a decision not to include it. The interim categories exist only because this formal process has not yet concluded for most nominated substances [1].
Important: January 2025 Policy Change
In January 2025, the FDA announced that it does not intend to place bulk drug substances nominated on or after January 7, 2025, into the three-category system [1]. New nominations are being evaluated through the standard rulemaking process rather than the interim policy framework. This signals a potential sunset of the category system as the FDA works through the backlog of existing nominations.
The 2023–2024 Reclassification: What Happened
Starting in September 2023, the FDA moved peptide substances from Category 1 to Category 2 at an unprecedented pace [3][4]. By February 2024, 17 peptides had been reclassified. Additional substances followed through December 2024, bringing the total to 19 [5].
The FDA's stated rationale included [4][5]:
- Immunogenicity concerns — the potential for certain injectable peptide compounds to trigger immune responses
- Manufacturing quality risks — concerns that compounding pharmacies may not adequately control for impurities during peptide synthesis
- Limited large-scale human clinical data — most affected substances had primarily preclinical or limited clinical evidence
- Specific documented adverse events — for some substances, the FDA cited reports of serious adverse events in its safety documentation
The scale and speed of these reclassifications was notable. Compounding pharmacy associations and industry groups challenged the FDA's approach, arguing that the agency had applied a blanket rationale rather than substance-specific safety analyses to justify many of the individual reclassifications [5][7].
The 2026 Reclassification Announcement: Current Status
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. stated publicly that approximately 14 of the 19 restricted peptides would be moved from Category 2 back to Category 1, restoring their eligibility for compounding under the FDA's interim enforcement discretion policy [4][5].
Kennedy's stated reasoning: the FDA was required to identify a specific safety signal to justify placing each substance in Category 2, and for most of the 19 substances, no such signal existed. The original restrictions, he argued, were based on a lack of efficacy data rather than evidence of harm — a different regulatory standard than the one the category system is designed to apply [4][5].
What has actually changed as of April 2026:
At the time of this writing, the formal regulatory action has not been completed. No updated category list has been published in the Federal Register. No official FDA bulletin has confirmed the specific substances affected or the implementation timeline [4][5].
The announcement represents stated policy intent from the head of HHS. It does not represent completed rulemaking or a published update to the 503A interim policy guidance.
What this means for the research landscape:
If the reclassification proceeds as described, substances that have been in Category 2 since 2023–2024 would return to Category 1 status, and the FDA would again exercise enforcement discretion regarding their use in compounding. However, until the formal action is published, the legal status of these substances has not officially changed.
The Role of the Pharmacy Compounding Advisory Committee (PCAC)
The PCAC is a federal advisory committee that provides recommendations to the FDA on compounding-related matters, including whether specific bulk drug substances should be included on the 503A bulks list [1][6].
The PCAC review process represents the formal evaluation pathway for substances moving toward potential inclusion on the bulks list. In 2024, the FDA referred several peptide substances to the PCAC for review at its October and December meetings — a step in the formal evaluation process that exists parallel to (and is more permanent than) category reclassification [6][7].
PCAC recommendations are advisory. The FDA is not bound by them but considers them as part of its evaluation process.
What the Categories Do Not Determine
It's worth being explicit about what the three-category system does not cover:
- It does not determine whether a substance is an approved drug. Category classification operates entirely within the compounding framework. Some substances may simultaneously exist as approved pharmaceuticals in other countries while being classified as Category 2 in the U.S. compounding system.
- It does not apply to Section 503B outsourcing facilities. The 503A categories govern traditional pharmacy compounding. Outsourcing facilities operating under Section 503B of the FD&C Act are subject to a separate regulatory framework.
- It does not regulate research chemical suppliers. The 503A framework applies specifically to compounding pharmacies preparing substances pursuant to prescriptions. The sale of substances for research purposes operates under a different regulatory context.
- It does not represent a scientific consensus on individual substances. The categories reflect the FDA's interim enforcement posture based on available evidence — not a final scientific determination about any specific compound.
Key Terms Glossary
503A Bulks List: The formal, finalized list of bulk drug substances authorized for compounding under Section 503A. Maintained through notice-and-comment rulemaking. Distinct from the interim categories.
Bulk Drug Substance: An active pharmaceutical ingredient or other substance intended for use in the compounding of a drug product.
Certificate of Analysis (COA): A document from a manufacturer or testing laboratory confirming the identity, purity, and quality specifications of a bulk drug substance.
Enforcement Discretion: A regulatory decision by the FDA not to take action against a particular activity — even if that activity technically falls outside formal authorization. Not a permanent legal right.
FD&C Act: The Federal Food, Drug, and Cosmetic Act — the primary federal statute governing drugs, food, medical devices, and cosmetics in the United States.
Interim Policy: A temporary FDA policy adopted to manage regulatory gaps while formal rulemaking is in progress.
PCAC: Pharmacy Compounding Advisory Committee — a federal advisory body that provides recommendations to the FDA on compounding policy and the 503A bulks list.
Section 503A: The section of the FD&C Act governing traditional pharmacy compounding by state-licensed pharmacies and physicians.
Section 503B: The section of the FD&C Act governing outsourcing facilities — a distinct regulatory category from 503A pharmacies.
Frequently Asked Questions
Is Category 1 the same as FDA approval?
No. Category 1 means the FDA has chosen not to take enforcement action against compounders using the substance while it continues to evaluate it. FDA approval requires a completed New Drug Application (NDA) with clinical trial data demonstrating that a specific drug product is both effective and acceptably characterized for its intended use.
Can a substance be in Category 2 and still be approved in other countries?
Yes. The FDA's category system applies specifically to the U.S. compounding framework under Section 503A. A substance's regulatory status in other countries is a separate determination by those countries' respective agencies.
Does Category 3 mean a substance is dangerous?
No. Category 3 indicates that the FDA received insufficient supporting information with the nomination to evaluate the substance. It reflects a documentation gap, not a safety finding.
How long does it take for a substance to move between categories?
There is no fixed timeline. Movement between categories depends on the FDA's evaluation process, the availability of supporting data, PCAC review schedules, and broader policy decisions. The 2023–2024 reclassification of 19 peptides to Category 2 occurred over approximately 15 months. The announced 2026 reversal, if finalized, would occur roughly two years after the initial restrictions began.
Will the three-category system continue indefinitely?
Possibly not. The FDA's January 2025 guidance stated that substances nominated on or after January 7, 2025, would not be placed into the category system [1]. This suggests the agency may be moving toward resolving existing nominations through formal rulemaking and phasing out the interim framework.
Source List / Citations
[1] U.S. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act (accessed April 11, 2026).
[2] U.S. Food and Drug Administration. "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A." FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and (accessed April 11, 2026).
[3] U.S. Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks." FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (accessed April 11, 2026).
[4] PeptideJournal.org. "FDA Peptide Ban Lifted: 14 Peptides Reclassified in 2026." March 7, 2026. https://www.peptidejournal.org/legal/fda-peptide-ban-lifted-2026-rfk-14-peptides-reclassified
[5] PeptideJournal.org. "FDA Peptide Regulation: Complete 2025–2026 Timeline." November 1, 2025, updated 2026. https://www.peptidejournal.org/legal/fda-peptide-regulation-complete-2025-2026-timeline
[6] Lexology / Buchanan Ingersoll & Rooney PC. "FDA Removes Certain Peptide Bulk Drug Substances from Category 2 and Sets Dates for PCAC Review." October 1, 2024. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
[7] Buchanan Ingersoll & Rooney PC. "Peptides at the Crossroads: FDA Tightens the Line as Category 2 Pushes Toward Category 1." April 2026. https://www.bipc.com/peptides-at-the-crossroads-fda-tightens-the-line-as-category-2-pushes-toward-category-1
[8] U.S. Food and Drug Administration. "503A Categories — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A." Updated September 27, 2024. https://www.fda.gov/media/94155/download
Secondary Disclaimer (RUO — Research Use Only)
Research Use Only Notice: Where specific compounds are referenced in this article, they are discussed in the context of their regulatory classification status and published research literature. References to specific substances do not constitute product recommendations. Compounds sold for research purposes are intended for laboratory and research use only and are not intended for human consumption. Any research-grade compounds available through commercial suppliers are sold strictly under Research Use Only (RUO) terms.
